What's Happening?
New research from Circana indicates that U.S. households using GLP-1 medications are adjusting their purchasing habits over time, rather than permanently reducing spending. The report, 'GLP-1 Unlocked:
The Next Phase of Consumer and Retail Transformation,' found that 37% of surveyed U.S. households have at least one member who has used GLP-1 medications, a significant increase from 17% in 2024. Currently, 30% of these households have a user. Initially, consumers change what, where, and how they buy, but their needs continue to evolve throughout the treatment journey. For instance, restaurant spending among GLP-1 households recovered to nearly pre-treatment levels in the second year, after an initial decline. Indulgent categories like candy and frozen desserts also showed recovery, with spending indices rising 5.7 and 5.3 points, respectively, above pre-treatment baselines by the second year. These figures measure spending relative to non-user households and do not represent percentage increases in actual household spending.
Why It's Important?
The evolving spending patterns of GLP-1 medication users present both challenges and opportunities for U.S. retailers and consumer goods manufacturers. The initial assumption that these consumers would consistently buy less is being disproven, as their needs and purchasing behaviors adapt over time. The recovery in restaurant and indulgent food spending suggests that businesses in these sectors may see a return to previous consumption levels, albeit with a potential shift in product preferences. Furthermore, the increased spending on apparel, footwear, and health technology among GLP-1 users highlights new growth areas. For example, 43% of households with a current GLP-1 user bought clothing or footwear, and 24% purchased a health device or wearable in the previous three months. This indicates a need for retailers to track consumer behavior throughout the treatment process to identify and capitalize on these shifting demands, rather than relying solely on initial trends.
What's Next?
Circana projects that GLP-1 households could account for a substantial portion of U.S. retail by 2030, specifically 40% of food and beverage units and 41% of non-food units, assuming continued adoption and current spending trends. This forecast underscores the critical need for retailers and manufacturers to develop agile strategies that cater to the evolving preferences of this consumer segment. Opportunities also exist for businesses to re-engage consumers who have previously used GLP-1 medications, as 48% of surveyed households with prior users indicated they were at least somewhat likely to resume treatment within the next year. This suggests a potential for recurring shifts in purchasing behavior, requiring ongoing market analysis and product adaptation. The research, which combines a 2026 GLP-1 household survey with omnichannel purchase data from August 2023 to July 2026, provides a foundation for understanding these future market dynamics.
Beyond the Headlines
The impact of GLP-1 medications extends beyond immediate retail sales, potentially influencing broader societal trends related to health, wellness, and consumer identity. As individuals experience changes in their health and body image due to these medications, their lifestyle choices, including fashion and technology adoption, are also evolving. This could lead to a long-term shift in demand for certain product categories and services, fostering innovation in areas like personalized nutrition, adaptive apparel, and integrated health tech solutions. The data also hints at a more nuanced understanding of consumer behavior, where health interventions can trigger a 'consumer reset' rather than a permanent reduction in consumption. This challenges traditional marketing approaches and emphasizes the importance of understanding the psychological and social dimensions of health-related consumer shifts, potentially leading to new ethical considerations for how products are marketed to this demographic.
